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This Article proposes a new direction for addressingfinancial conflicts of interest,
which plague biomedical research and threaten scientific integrity. This Article
descriptively states the controversy surrounding financial conflicts of interest by
explaining how these conflicts arise and the damage that can be created as a result. By
describing the scientific process, the Article explains that changes to the academic
environment may allow the public-private interaction to proceed, without creating the
problems associated with financial conflicts of interest.
Financial conflicts of interest are created when the profit-seeking motive of a private

funding source unduly influences an academic scientist's primary responsibilities. The
problem with financial conflicts of interest has grown since the passage of the BayhDole Act in 1980. The cornerstone of currentpolicies to address financial conflicts of
interest is disclosure, which is inadequate and unsatisfying.
The analysis herein changes the trajectory of current approaches in this area by
proposing that an analysis of the underlying environment and behavior leading to
conflicts of interest must be considered. This Article proposes the use of behavioral
economics to craft a policy that effectively addresses conflicts of interest. To this end,
this Article applies research from the field of psychology to understand both the
environment of academic scientists as well as to begin to understand how academic
scientists make decisions. Drawing on psychology literature,this articleproposes that
academic scientists may experience cognitive dissonance when faced with a situation in
which a conflict of interest may arise. This helps to understand why an academic
scientistmay make a decision that creates a conflict of interest. In addition, this Article
utilizes the results of an empirical study conducted by myself and a colleague. In this
study, we asked faculty at five medical schools to respond to an anonymous survey
containing hypothetical situations in which a conflict may arise. The combination of
the psychology literatureand our empirical study can provide support to the creation of
new policies.
Policy proposals include implementation of default rules, education, and changes to
academic requirements. Furthermore,this Article considers ways to incentivize medical
centers to implement effective policies as well as changes to intellectual property law.
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Over the past century, medical advancements have resulted in tremendous health gains
for Americans. Although the federal government has played a prominent role in
ensuring that new treatments are safe and effective, questions about which medical
treatments work best under which circumstances have largely remained unanswered.
Thus, the federal government's recent major investments in comparative-effectiveness
researchhave potential to play a significantrole in helping both patients and health care
providers navigate the vast array of available treatment options, as well as in improving
the quality, efficiency, and delivery of health care system-wide. Yet, the controversial
nature of the government's foray into comparative-effectiveness research also suggests
that the path toward realizing these goals may be treacherous. This Article describes the
rationales for federal support of comparative-effectiveness research and potential
models for that involvement, analyzes the federal government's recent investments in
the research, and concludes with predictions about the probable outcomes of these
investments. While increased federal support for comparative-effectiveness research is
unlikely to achieve all of the benefits anticipated by its supporters, it is a crucial step
toward ensuring that Americans are able to take full advantage of the benefits of
medical innovation
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The idea that genetic information is different from other medical information and
therefore needs specialprotection has led to a regulatorypuzzle where genetic testing is
currently regulated under three separateschemes. Although genetic tests for over 2,000
diseases are available, less than 10% of these tests have been reviewed for clinical
validity or utility. Recent action by some genetic testing companies has prompted the
federal government to propose changes to the current regulatory scheme. This article
discusses the currentframework and the recent developments before examining some of
the concerns and challenges that face the implementation of these proposed changes.
The author evaluates the proposals and competing interests in order to suggest how
genetic testing may best be regulated to meet the needs of the industry, clinicians,
researchers,patients, and consumers.
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Most tobacco control laws were written to address the scourge of smoking - particularly
smoking cigarettes. As a result, these laws frequently exclude non-cigarette tobacco
products, which are becoming more prevalent on the market. These regulatory gaps
jeopardize public health by increasing the possibility that these products will be used particularlyby minors and young adults. This article examines gaps in regulationusing
five products as case studies: dissolvable tobacco products, electronic cigarettes, little
cigars, snus, and water pipes. In addition, this articlepresents policy options that state
and local governments can adopt to regulate these products more effectively, including
regulations relating to price, flavors, youth access, use in public places, point-of-sale
warnings, and marketing. Furthermore,this article contains extensive discussion of the
recently adopted federal Family Smoking Prevention and Tobacco Control Act, which
both limits and expands the power of state and local governments.
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In 2011, the United States Supreme Court in Sorrell v. IMS Health Inc. struck down a
Vermont law that would restrict the ability of pharmaceuticalcompanies to purchase
certain physician-identifiableprescription data without the consent of the prescriber.
The law's stated purpose was threefold: to protect the privacy of medical information, to
protect the public health and to contain healthcare costs by promoting Vermont's
preference in having physicians prescribe more generic drugs. The issue before the
Supreme Court was whether the Vermont law represented a legitimate, common sense
regulatory program or a bold attempt to suppress commercial speech when the
"message" is disfavored by the state. Striking down the law, the Supreme Court applied
a heightened level of First Amendment scrutiny to this commercial transactionand held
that the Vermont law was not narrowly tailored to protect legitimate privacy interests.

Can the FDA Improve Oversight of Foreign
Clinical Trials?: Closing the Information Gap
and Moving Towards a Globalized
.......................
Regulatory Scheme

ANDR

OURSo

493

Currently, pharmaceutical companies' utilization of foreign clinical trial data is a
ubiquitous and indispensable aspect of gainingapproval to market drugs in the United
States. Cost benefits, a largerpool of ready volunteer subjects, and greaterefficiency in
clinical testing are some of the reasons for conducting clinical trials overseas. Despite
these advantages, lack of proper oversight may have seriouspublic health implications
regarding the integrity of clinical research, ethical treatment of human subjects, and
drug safety. Due to the expansive global nature of foreign clinical trials, there are
concerns with the FDA's ability to monitor and regulate these trials. This article
examines the FDA's oversight of foreign clinical trials and the agency's limitations
regulatingthese trials. In addition to looking at steps the FDA is taking to address these
limitations, the article examines other potential regulatory and cooperativeactions that
can be taken to effectively monitor foreign clinical trials and to ensure data integrity and
patient safety.
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